A major blow was struck against the enclosure of global health this weekend as patents for the blockbuster weight-loss drug semaglutide expired in India and China. For years, the pharmaceutical giant Novo Nordisk has maintained a stranglehold on these life-altering medications, charging upward of one thousand dollars per month in the United States and hundreds of dollars in developing markets. This weekend, that corporate grip was broken. Generic manufacturers in India are poised to release versions of Ozempic and Wegovy for as little as fourteen dollars a month, a price point that brings the drug within reach of billions of people.

This democratization of medicine is a vital victory for the Global South. For too long, the right to health has been a commodity reserved for the wealthy elites of high-income nations. Activists in New Delhi have rightly hailed this moment as a triumph of human need over the artificial scarcity created by intellectual property laws. By removing the financial barriers to diabetes and obesity treatment, these nations are providing a roadmap for a world where medical innovation is treated as a public good rather than a vehicle for shareholder extraction.

Predictably, Novo Nordisk has attempted to protect its margins by positioning its original products as a premium brand, a desperate marketing tactic designed to maintain a class-based tier of healthcare. They have also engaged in aggressive litigation to block generic entry in Brazil and elsewhere. However, the sheer scale of the generic wave is unstoppable. With fifty generic brands expected to enter the Indian market alone, the era of pharmaceutical rent-seeking for this class of drugs is coming to an end. This victory demonstrates the power of the Global South to dictate its own health future when it refuses to bow to the demands of Western capital.